HB Therapeutics, inc.
June 22, 2026
Theater 2
Type: Company Presentation
Focus Area:
Oncology
HB Therapeutics is a biotechnology company developing next-generation targeted protein degradation therapies for KRAS-driven cancers. The company leverages novel E3 ligase biology and molecular glue chemistry to develop multi-node co-degraders designed to simultaneously eliminate KRAS mutants and adaptive escape pathway proteins such as CRAF. HB Therapeutics’ lead programs focus on KRAS-driven solid tumors, including pancreatic, colorectal, and lung cancers. The platform integrates CRISPR-enabled ligase discovery, translational oncology models, and medicinal chemistry optimization to develop differentiated degradation strategies with the potential to address resistance mechanisms associated with current KRAS-targeting therapies. Early studies have demonstrated selective KRASmut/CRAF co-degradation, robust in vivo target engagement, and proof-of-concept anti-tumor activity.
Company HQ City:
Indianapolis
Company HQ State:
IN
Company HQ Country:
United States
Year Founded:
2018
Lead Product in Development:
KRASmut/CRAF Molecular Glue Co-Degrader
CEO
Anita Bellail
Development Phase of Lead Product
Pre-Clinical
When you expect your next catalyst update?
June 2027
What is your next catalyst (value inflection) update?
Development candidate nomination for the KRASmut/CRAF molecular glue co-degrader program, supported by ongoing lead optimization, additional in vivo proof-of-concept studies, and advancement toward IND-enabling development.
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}